Key clinical point: Metabolic syndrome (MetS) and obesity in individuals aged between 20 and 49 years are associated with an increased risk for earlier-onset colorectal cancer (CRC).

Major finding: MetS (adjusted hazard ratio [aHR] 1.20; 95% CI 1.14-1.27) and a higher body mass index (BMI; 25.0-29.9 kg/m²: aHR 1.19; 95% CI 1.12-1.25; ≥30 kg/m²: aHR 1.45; 95% CI 1.31-1.61) and waist circumference (WC; ≥100 cm in men or ≥95 cm in women: aHR 1.53; 95% CI 1.34-1.74) were associated with an increased earlier-onset CRC risk.

Study details: Findings are from a nationwide population-based cohort study that enrolled 5,672,153 individuals aged 20-49 years with health checkup data (i.e., anthropometric measurement, laboratory test, and health behavior data), of which 8320 developed earlier-onset CRC.

Disclosures: The study received no funding. The authors declared no conflicts of interest.

Source: Jin EH et al. Association between metabolic syndrome and the risk of colorectal cancer diagnosed before 50 years according to tumor location. Gastroenterology. 2022 (May 26). Doi: 10.1053/j.gastro.2022.05.032

Key clinical point: Metabolic syndrome (MetS) and obesity in individuals aged between 20 and 49 years are associated with an increased risk for earlier-onset colorectal cancer (CRC).

Major finding: MetS (adjusted hazard ratio [aHR] 1.20; 95% CI 1.14-1.27) and a higher body mass index (BMI; 25.0-29.9 kg/m²: aHR 1.19; 95% CI 1.12-1.25; ≥30 kg/m²: aHR 1.45; 95% CI 1.31-1.61) and waist circumference (WC; ≥100 cm in men or ≥95 cm in women: aHR 1.53; 95% CI 1.34-1.74) were associated with an increased earlier-onset CRC risk.

Study details: Findings are from a nationwide population-based cohort study that enrolled 5,672,153 individuals aged 20-49 years with health checkup data (i.e., anthropometric measurement, laboratory test, and health behavior data), of which 8320 developed earlier-onset CRC.

Disclosures: The study received no funding. The authors declared no conflicts of interest.

Source: Jin EH et al. Association between metabolic syndrome and the risk of colorectal cancer diagnosed before 50 years according to tumor location. Gastroenterology. 2022 (May 26). Doi: 10.1053/j.gastro.2022.05.032

Key clinical point: Metabolic syndrome (MetS) and obesity in individuals aged between 20 and 49 years are associated with an increased risk for earlier-onset colorectal cancer (CRC).

Major finding: MetS (adjusted hazard ratio [aHR] 1.20; 95% CI 1.14-1.27) and a higher body mass index (BMI; 25.0-29.9 kg/m²: aHR 1.19; 95% CI 1.12-1.25; ≥30 kg/m²: aHR 1.45; 95% CI 1.31-1.61) and waist circumference (WC; ≥100 cm in men or ≥95 cm in women: aHR 1.53; 95% CI 1.34-1.74) were associated with an increased earlier-onset CRC risk.

Study details: Findings are from a nationwide population-based cohort study that enrolled 5,672,153 individuals aged 20-49 years with health checkup data (i.e., anthropometric measurement, laboratory test, and health behavior data), of which 8320 developed earlier-onset CRC.

Disclosures: The study received no funding. The authors declared no conflicts of interest.

Source: Jin EH et al. Association between metabolic syndrome and the risk of colorectal cancer diagnosed before 50 years according to tumor location. Gastroenterology. 2022 (May 26). Doi: 10.1053/j.gastro.2022.05.032

Key clinical point: Individuals with the highest vs. lowest intake of nuts and legumes had a 16% and 10% lower risk for colorectal cancer (CRC), respectively.

Major finding: The pooled relative risk (RR) for CRC among individuals with the highest vs. lowest consumption of nuts and legumes was 0.84 (95% CI 0.71-0.99) and 0.90 (95% CI 0.83-0.98), respectively. A once-daily consumption of 28 g nuts and 100 g legumes was associated with a 33% (RR 0.67; 95% CI 0.45-0.98) and 21% (RR 0.79; 95% CI 0.64-0.97) lower risk for CRC, respectively.

Study details: Findings are from a meta-analysis of 13 and 29 studies that evaluated the association of the consumption of nuts and legumes with CRC risk, respectively.

Disclosures: The study was supported by the National Research Foundation of Korea, Ministry of Science, ICT, and Future Planning. The authors declared no conflicts of interest.

Source: Jin S,  Je Y. Nuts and legumes consumption and risk of colorectal cancer: A systematic review and meta-analysis. Eur J Epidemiol. 2022 (May 27). Doi: 10.1007/s10654-022-00881-6

Key clinical point: Individuals with the highest vs. lowest intake of nuts and legumes had a 16% and 10% lower risk for colorectal cancer (CRC), respectively.

Major finding: The pooled relative risk (RR) for CRC among individuals with the highest vs. lowest consumption of nuts and legumes was 0.84 (95% CI 0.71-0.99) and 0.90 (95% CI 0.83-0.98), respectively. A once-daily consumption of 28 g nuts and 100 g legumes was associated with a 33% (RR 0.67; 95% CI 0.45-0.98) and 21% (RR 0.79; 95% CI 0.64-0.97) lower risk for CRC, respectively.

Study details: Findings are from a meta-analysis of 13 and 29 studies that evaluated the association of the consumption of nuts and legumes with CRC risk, respectively.

Disclosures: The study was supported by the National Research Foundation of Korea, Ministry of Science, ICT, and Future Planning. The authors declared no conflicts of interest.

Source: Jin S,  Je Y. Nuts and legumes consumption and risk of colorectal cancer: A systematic review and meta-analysis. Eur J Epidemiol. 2022 (May 27). Doi: 10.1007/s10654-022-00881-6

Key clinical point: Individuals with the highest vs. lowest intake of nuts and legumes had a 16% and 10% lower risk for colorectal cancer (CRC), respectively.

Major finding: The pooled relative risk (RR) for CRC among individuals with the highest vs. lowest consumption of nuts and legumes was 0.84 (95% CI 0.71-0.99) and 0.90 (95% CI 0.83-0.98), respectively. A once-daily consumption of 28 g nuts and 100 g legumes was associated with a 33% (RR 0.67; 95% CI 0.45-0.98) and 21% (RR 0.79; 95% CI 0.64-0.97) lower risk for CRC, respectively.

Study details: Findings are from a meta-analysis of 13 and 29 studies that evaluated the association of the consumption of nuts and legumes with CRC risk, respectively.

Disclosures: The study was supported by the National Research Foundation of Korea, Ministry of Science, ICT, and Future Planning. The authors declared no conflicts of interest.

Source: Jin S,  Je Y. Nuts and legumes consumption and risk of colorectal cancer: A systematic review and meta-analysis. Eur J Epidemiol. 2022 (May 27). Doi: 10.1007/s10654-022-00881-6

Key clinical point: Compared with hybrid and open resection, simultaneous laparoscopic resection of colorectal cancer (CRC) and liver metastases offers improved postoperative outcomes and equivalent long-term oncological outcomes.

Major finding: The laparoscopic group had a lower wound complication rate than the open group (2.1% vs. 13.2%; P = .028) and a shorter postoperative hospital stay than the hybrid and open groups (8 vs. 11 days; P < .001 for both). The 5-year liver-specific recurrence rates were similar between the laparoscopic and hybrid groups (P = .270) and between the laparoscopic and open groups (P = .391).

Study details: The data come from a retrospective study including 647 patients who underwent simultaneous surgery for primary CRC and synchronous liver metastases and were categorized into the laparoscopic (n = 42) vs. hybrid (n = 81) and laparoscopic (n = 48) vs. open (n = 136) group sets after propensity score matching.

Disclosures: The study received no financial support. The authors declared no conflicts of interest.

Source: Lim H-K et al. Outcomes of simultaneous laparoscopic, hybrid, and open resection in colorectal cancer with synchronous liver metastases: a propensity score-matched study. Sci Rep. 2022;12:8867 (May 25). Doi: 10.1038/s41598-022-12372-5

Key clinical point: Compared with hybrid and open resection, simultaneous laparoscopic resection of colorectal cancer (CRC) and liver metastases offers improved postoperative outcomes and equivalent long-term oncological outcomes.

Major finding: The laparoscopic group had a lower wound complication rate than the open group (2.1% vs. 13.2%; P = .028) and a shorter postoperative hospital stay than the hybrid and open groups (8 vs. 11 days; P < .001 for both). The 5-year liver-specific recurrence rates were similar between the laparoscopic and hybrid groups (P = .270) and between the laparoscopic and open groups (P = .391).

Study details: The data come from a retrospective study including 647 patients who underwent simultaneous surgery for primary CRC and synchronous liver metastases and were categorized into the laparoscopic (n = 42) vs. hybrid (n = 81) and laparoscopic (n = 48) vs. open (n = 136) group sets after propensity score matching.

Disclosures: The study received no financial support. The authors declared no conflicts of interest.

Source: Lim H-K et al. Outcomes of simultaneous laparoscopic, hybrid, and open resection in colorectal cancer with synchronous liver metastases: a propensity score-matched study. Sci Rep. 2022;12:8867 (May 25). Doi: 10.1038/s41598-022-12372-5

Key clinical point: Compared with hybrid and open resection, simultaneous laparoscopic resection of colorectal cancer (CRC) and liver metastases offers improved postoperative outcomes and equivalent long-term oncological outcomes.

Major finding: The laparoscopic group had a lower wound complication rate than the open group (2.1% vs. 13.2%; P = .028) and a shorter postoperative hospital stay than the hybrid and open groups (8 vs. 11 days; P < .001 for both). The 5-year liver-specific recurrence rates were similar between the laparoscopic and hybrid groups (P = .270) and between the laparoscopic and open groups (P = .391).

Study details: The data come from a retrospective study including 647 patients who underwent simultaneous surgery for primary CRC and synchronous liver metastases and were categorized into the laparoscopic (n = 42) vs. hybrid (n = 81) and laparoscopic (n = 48) vs. open (n = 136) group sets after propensity score matching.

Disclosures: The study received no financial support. The authors declared no conflicts of interest.

Source: Lim H-K et al. Outcomes of simultaneous laparoscopic, hybrid, and open resection in colorectal cancer with synchronous liver metastases: a propensity score-matched study. Sci Rep. 2022;12:8867 (May 25). Doi: 10.1038/s41598-022-12372-5

Key clinical point: Compared with regorafenib, raltitrexed plus S-1 (RS) prolonged overall survival without causing unmanageable adverse effects in patients with metastatic colorectal cancer (mCRC) who did not respond to previous standard treatments.

Major finding: Patients receiving RS vs. regorafenib had a significantly longer overall survival (13.3 vs. 10.0 months; P = .02). Adverse events were well tolerated in both the groups.

Study details: The findings are from a real-world, retrospective cohort study including 187 adult patients with mCRC who received RS or regorafenib after the failure of ≥2 standard treatments and were propensity score-matched to form 78 pairs.

Disclosures: This study was sponsored by the Sichuan Science and Technology Department Key Research and Development Project, among others. The authors declared no conflicts of interest.

Source: Zhou Y-W et al. Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study. Therap Adv Gastroenterol. 2022 (May 18). Doi: 10.1177/17562848221098246

Key clinical point: Compared with regorafenib, raltitrexed plus S-1 (RS) prolonged overall survival without causing unmanageable adverse effects in patients with metastatic colorectal cancer (mCRC) who did not respond to previous standard treatments.

Major finding: Patients receiving RS vs. regorafenib had a significantly longer overall survival (13.3 vs. 10.0 months; P = .02). Adverse events were well tolerated in both the groups.

Study details: The findings are from a real-world, retrospective cohort study including 187 adult patients with mCRC who received RS or regorafenib after the failure of ≥2 standard treatments and were propensity score-matched to form 78 pairs.

Disclosures: This study was sponsored by the Sichuan Science and Technology Department Key Research and Development Project, among others. The authors declared no conflicts of interest.

Source: Zhou Y-W et al. Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study. Therap Adv Gastroenterol. 2022 (May 18). Doi: 10.1177/17562848221098246

Key clinical point: Compared with regorafenib, raltitrexed plus S-1 (RS) prolonged overall survival without causing unmanageable adverse effects in patients with metastatic colorectal cancer (mCRC) who did not respond to previous standard treatments.

Major finding: Patients receiving RS vs. regorafenib had a significantly longer overall survival (13.3 vs. 10.0 months; P = .02). Adverse events were well tolerated in both the groups.

Study details: The findings are from a real-world, retrospective cohort study including 187 adult patients with mCRC who received RS or regorafenib after the failure of ≥2 standard treatments and were propensity score-matched to form 78 pairs.

Disclosures: This study was sponsored by the Sichuan Science and Technology Department Key Research and Development Project, among others. The authors declared no conflicts of interest.

Source: Zhou Y-W et al. Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study. Therap Adv Gastroenterol. 2022 (May 18). Doi: 10.1177/17562848221098246

Key clinical point: Heavy alcohol use strongly contributes to increased early-onset colorectal cancer (EOCRC) risk irrespective of polygenic risk score (PRS) levels. Abstinence from heavy drinking may reduce EOCRC risk to a degree equivalent to having a much lower genetic risk.

Major finding: High (≥25 g/day) vs. low (0.1 to <25 g/day) lifetime average alcohol consumption was strongly associated with increased EOCRC risk (odds ratio 1.8; 95% CI 1.2-2.8). The effect of high lifetime alcohol consumption on EOCRC was equivalent to that of having 47 percentiles higher PRS (genetic risk equivalent 47; 95% CI 12-82).

Study details: This retrospective study included 5104 patients with colorectal cancer and 4131 non-colorectal cancer controls from the large, population-based German DACHS study.

Disclosures: The DACHS study was supported by the German Research Council and German Federal Ministry of Education and Research. The authors declared no conflicts of interest.

Source: Chen X et al. Alcohol consumption, polygenic risk score, and early- and late-onset colorectal cancer risk. EClinicalMedicine. 2022;49:101460 (May 20). Doi: 10.1016/j.eclinm.2022.101460

Key clinical point: Heavy alcohol use strongly contributes to increased early-onset colorectal cancer (EOCRC) risk irrespective of polygenic risk score (PRS) levels. Abstinence from heavy drinking may reduce EOCRC risk to a degree equivalent to having a much lower genetic risk.

Major finding: High (≥25 g/day) vs. low (0.1 to <25 g/day) lifetime average alcohol consumption was strongly associated with increased EOCRC risk (odds ratio 1.8; 95% CI 1.2-2.8). The effect of high lifetime alcohol consumption on EOCRC was equivalent to that of having 47 percentiles higher PRS (genetic risk equivalent 47; 95% CI 12-82).

Study details: This retrospective study included 5104 patients with colorectal cancer and 4131 non-colorectal cancer controls from the large, population-based German DACHS study.

Disclosures: The DACHS study was supported by the German Research Council and German Federal Ministry of Education and Research. The authors declared no conflicts of interest.

Source: Chen X et al. Alcohol consumption, polygenic risk score, and early- and late-onset colorectal cancer risk. EClinicalMedicine. 2022;49:101460 (May 20). Doi: 10.1016/j.eclinm.2022.101460

Key clinical point: Heavy alcohol use strongly contributes to increased early-onset colorectal cancer (EOCRC) risk irrespective of polygenic risk score (PRS) levels. Abstinence from heavy drinking may reduce EOCRC risk to a degree equivalent to having a much lower genetic risk.

Major finding: High (≥25 g/day) vs. low (0.1 to <25 g/day) lifetime average alcohol consumption was strongly associated with increased EOCRC risk (odds ratio 1.8; 95% CI 1.2-2.8). The effect of high lifetime alcohol consumption on EOCRC was equivalent to that of having 47 percentiles higher PRS (genetic risk equivalent 47; 95% CI 12-82).

Study details: This retrospective study included 5104 patients with colorectal cancer and 4131 non-colorectal cancer controls from the large, population-based German DACHS study.

Disclosures: The DACHS study was supported by the German Research Council and German Federal Ministry of Education and Research. The authors declared no conflicts of interest.

Source: Chen X et al. Alcohol consumption, polygenic risk score, and early- and late-onset colorectal cancer risk. EClinicalMedicine. 2022;49:101460 (May 20). Doi: 10.1016/j.eclinm.2022.101460

Key clinical point: The association between metachronous colorectal cancer (CRC) diagnosis and biopsy of nontumor sites after biopsy of an initial CRC in the same colonoscopy is not significant.

Major finding: Nontumor site biopsy after initial CRC biopsy was not significantly associated with the risk for metachronous CRC in the colonic segment of the additional biopsy site (adjusted odds ratio 2.29; 95% CI 0.77-6.81).

Study details: This retrospective case-control study included 45 adult patients, diagnosed with CRC by colonoscopy with biopsy who underwent complete curative resection and were re-diagnosed with CRC within 6 months to 4 years of the initial diagnosis, and 212 matched control individuals.

Disclosures: The study was supported by the Population-based Research to Optimize the Screening Process Consortium, US National Cancer Institute. The authors declared no conflicts of interest.

Source: Lam AY et al. Biopsy of non-tumor sites after biopsy of a colorectal cancer is not associated with metachronous cancers: a case-control study. Clin Gastroenterol Hepatol. 2022 (May 26). Doi: 10.1016/j.cgh.2022.05.006

Key clinical point: The association between metachronous colorectal cancer (CRC) diagnosis and biopsy of nontumor sites after biopsy of an initial CRC in the same colonoscopy is not significant.

Major finding: Nontumor site biopsy after initial CRC biopsy was not significantly associated with the risk for metachronous CRC in the colonic segment of the additional biopsy site (adjusted odds ratio 2.29; 95% CI 0.77-6.81).

Study details: This retrospective case-control study included 45 adult patients, diagnosed with CRC by colonoscopy with biopsy who underwent complete curative resection and were re-diagnosed with CRC within 6 months to 4 years of the initial diagnosis, and 212 matched control individuals.

Disclosures: The study was supported by the Population-based Research to Optimize the Screening Process Consortium, US National Cancer Institute. The authors declared no conflicts of interest.

Source: Lam AY et al. Biopsy of non-tumor sites after biopsy of a colorectal cancer is not associated with metachronous cancers: a case-control study. Clin Gastroenterol Hepatol. 2022 (May 26). Doi: 10.1016/j.cgh.2022.05.006

Key clinical point: The association between metachronous colorectal cancer (CRC) diagnosis and biopsy of nontumor sites after biopsy of an initial CRC in the same colonoscopy is not significant.

Major finding: Nontumor site biopsy after initial CRC biopsy was not significantly associated with the risk for metachronous CRC in the colonic segment of the additional biopsy site (adjusted odds ratio 2.29; 95% CI 0.77-6.81).

Study details: This retrospective case-control study included 45 adult patients, diagnosed with CRC by colonoscopy with biopsy who underwent complete curative resection and were re-diagnosed with CRC within 6 months to 4 years of the initial diagnosis, and 212 matched control individuals.

Disclosures: The study was supported by the Population-based Research to Optimize the Screening Process Consortium, US National Cancer Institute. The authors declared no conflicts of interest.

Source: Lam AY et al. Biopsy of non-tumor sites after biopsy of a colorectal cancer is not associated with metachronous cancers: a case-control study. Clin Gastroenterol Hepatol. 2022 (May 26). Doi: 10.1016/j.cgh.2022.05.006

Key clinical point: Patients with metastatic colorectal cancer (mCRC) show a clear-cut attrition across subsequent lines of therapy, with most patients with RAS/BRAF wild-type mCRC opting for anti-epidermal growth factor receptor (EGFR)-containing regimens as the treatment of choice after the second progressive disease (PD).

Major finding: The number of patients receiving subsequent systemic treatment decreased with each progressive line of therapy (53%, 27%, and 11% of patients received treatment after the second, third, and fourth PD, respectively). After the second PD, anti-EGFR-containing regimens were preferred by most (67%) patients with RAS/BRAF wild-type mCRC.

Study details: This pooled analysis study included 1187 patients with mCRC from two phase 3 trials, TRIBE and TRIBE2, who received fluorouracil, irinotecan, and oxaliplatin (FOLFOXIRI) + bevacizumab or doublets (fluorouracil + oxaliplatin [FOLFOX] or fluorouracil + irinotecan [FOLFIRI]) + bevacizumab as the first-line therapy.

Disclosures: The study was supported by the GONO and ARCO Foundations. Some authors declared serving as consultants, advisors, or speakers for or receiving honoraria or research funding from various organizations.

Source: Rossini D et al. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. Eur J Cancer. 2022;170:64-72 (May 17). Doi: 10.1016/j.ejca.2022.04.019

Key clinical point: Patients with metastatic colorectal cancer (mCRC) show a clear-cut attrition across subsequent lines of therapy, with most patients with RAS/BRAF wild-type mCRC opting for anti-epidermal growth factor receptor (EGFR)-containing regimens as the treatment of choice after the second progressive disease (PD).

Major finding: The number of patients receiving subsequent systemic treatment decreased with each progressive line of therapy (53%, 27%, and 11% of patients received treatment after the second, third, and fourth PD, respectively). After the second PD, anti-EGFR-containing regimens were preferred by most (67%) patients with RAS/BRAF wild-type mCRC.

Study details: This pooled analysis study included 1187 patients with mCRC from two phase 3 trials, TRIBE and TRIBE2, who received fluorouracil, irinotecan, and oxaliplatin (FOLFOXIRI) + bevacizumab or doublets (fluorouracil + oxaliplatin [FOLFOX] or fluorouracil + irinotecan [FOLFIRI]) + bevacizumab as the first-line therapy.

Disclosures: The study was supported by the GONO and ARCO Foundations. Some authors declared serving as consultants, advisors, or speakers for or receiving honoraria or research funding from various organizations.

Source: Rossini D et al. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. Eur J Cancer. 2022;170:64-72 (May 17). Doi: 10.1016/j.ejca.2022.04.019

Key clinical point: Patients with metastatic colorectal cancer (mCRC) show a clear-cut attrition across subsequent lines of therapy, with most patients with RAS/BRAF wild-type mCRC opting for anti-epidermal growth factor receptor (EGFR)-containing regimens as the treatment of choice after the second progressive disease (PD).

Major finding: The number of patients receiving subsequent systemic treatment decreased with each progressive line of therapy (53%, 27%, and 11% of patients received treatment after the second, third, and fourth PD, respectively). After the second PD, anti-EGFR-containing regimens were preferred by most (67%) patients with RAS/BRAF wild-type mCRC.

Study details: This pooled analysis study included 1187 patients with mCRC from two phase 3 trials, TRIBE and TRIBE2, who received fluorouracil, irinotecan, and oxaliplatin (FOLFOXIRI) + bevacizumab or doublets (fluorouracil + oxaliplatin [FOLFOX] or fluorouracil + irinotecan [FOLFIRI]) + bevacizumab as the first-line therapy.

Disclosures: The study was supported by the GONO and ARCO Foundations. Some authors declared serving as consultants, advisors, or speakers for or receiving honoraria or research funding from various organizations.

Source: Rossini D et al. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. Eur J Cancer. 2022;170:64-72 (May 17). Doi: 10.1016/j.ejca.2022.04.019

Key clinical point: The addition of atezolizumab to the first-line FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) + bevacizumab improved progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer (mCRC) without compromising safety.

Major finding: At a median follow-up of 19.9 months, patients receiving FOLFOXIRI + bevacizumab and atezolizumab vs. FOLFOXIRI + bevacizumab had a significantly longer median PFS (13.1 vs. 11.5 months; adjusted hazard ratio 0.70; P = .018), with serious adverse events being reported in 27% vs. 26% of patients, respectively.

Study details: The data come from a phase 2 study, AtezoTRIBE, that included 218 adult patients with previously untreated mCRC who were randomly assigned to receive FOLFOXIRI + bevacizumab (n = 73) or FOLFOXIRI + bevacizumab and atezolizumab (n = 145).

Disclosures: The study was sponsored by the GONO and ARCO Foundations, F Hoffmann-La Roche, and Roche. Some authors declared serving as consultants/advisors for or receiving honoraria or speaker/consulting fees from various sources, including Roche.

Source: Antoniotti C et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022 (May 27). Doi: 10.1016/S1470-2045(22)00274-1

Key clinical point: The addition of atezolizumab to the first-line FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) + bevacizumab improved progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer (mCRC) without compromising safety.

Major finding: At a median follow-up of 19.9 months, patients receiving FOLFOXIRI + bevacizumab and atezolizumab vs. FOLFOXIRI + bevacizumab had a significantly longer median PFS (13.1 vs. 11.5 months; adjusted hazard ratio 0.70; P = .018), with serious adverse events being reported in 27% vs. 26% of patients, respectively.

Study details: The data come from a phase 2 study, AtezoTRIBE, that included 218 adult patients with previously untreated mCRC who were randomly assigned to receive FOLFOXIRI + bevacizumab (n = 73) or FOLFOXIRI + bevacizumab and atezolizumab (n = 145).

Disclosures: The study was sponsored by the GONO and ARCO Foundations, F Hoffmann-La Roche, and Roche. Some authors declared serving as consultants/advisors for or receiving honoraria or speaker/consulting fees from various sources, including Roche.

Source: Antoniotti C et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022 (May 27). Doi: 10.1016/S1470-2045(22)00274-1

Key clinical point: The addition of atezolizumab to the first-line FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) + bevacizumab improved progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer (mCRC) without compromising safety.

Major finding: At a median follow-up of 19.9 months, patients receiving FOLFOXIRI + bevacizumab and atezolizumab vs. FOLFOXIRI + bevacizumab had a significantly longer median PFS (13.1 vs. 11.5 months; adjusted hazard ratio 0.70; P = .018), with serious adverse events being reported in 27% vs. 26% of patients, respectively.

Study details: The data come from a phase 2 study, AtezoTRIBE, that included 218 adult patients with previously untreated mCRC who were randomly assigned to receive FOLFOXIRI + bevacizumab (n = 73) or FOLFOXIRI + bevacizumab and atezolizumab (n = 145).

Disclosures: The study was sponsored by the GONO and ARCO Foundations, F Hoffmann-La Roche, and Roche. Some authors declared serving as consultants/advisors for or receiving honoraria or speaker/consulting fees from various sources, including Roche.

Source: Antoniotti C et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022 (May 27). Doi: 10.1016/S1470-2045(22)00274-1

Key clinical point: The modified triplet (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan [mFOLFOXIRI]) + panitumumab vs. the doublet (fluorouracil, leucovorin, and oxaliplatin [FOLFOX]) + panitumumab does not show improved activity as initial therapy for RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC).

Major finding: Patients receiving mFOLFOXIRI + panitumumab vs. FOLFOX + panitumumab showed no significant difference in the objective response rate (73% vs. 76%; odds ratio 0.87; P = .526) and median progression-free survival (12.7 vs. 12.3 months; hazard ratio 0.88; P = .277).

Study details: Findings are from the phase 3 TRIPLETE study that included 435 adult patients with RAS and BRAF wt mCRC who were randomly assigned to receive mFOLFOXIRI + panitumumab (n = 218) or FOLFOX + panitumumab (n = 217).

Disclosures: The study was supported by the GONO Foundation and Amgen. Some authors declared serving as consultants/advisors or members of the speaker's bureau for or receiving honoraria, research funding, or travel and accommodation fees from various sources, including Amgen.

Source: Rossini D et al. Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer: The phase III TRIPLETE Study by GONO. J Clin Oncol. 2022 (Jun 6). Doi: 10.1200/JCO.22.00839

Key clinical point: The modified triplet (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan [mFOLFOXIRI]) + panitumumab vs. the doublet (fluorouracil, leucovorin, and oxaliplatin [FOLFOX]) + panitumumab does not show improved activity as initial therapy for RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC).

Major finding: Patients receiving mFOLFOXIRI + panitumumab vs. FOLFOX + panitumumab showed no significant difference in the objective response rate (73% vs. 76%; odds ratio 0.87; P = .526) and median progression-free survival (12.7 vs. 12.3 months; hazard ratio 0.88; P = .277).

Study details: Findings are from the phase 3 TRIPLETE study that included 435 adult patients with RAS and BRAF wt mCRC who were randomly assigned to receive mFOLFOXIRI + panitumumab (n = 218) or FOLFOX + panitumumab (n = 217).

Disclosures: The study was supported by the GONO Foundation and Amgen. Some authors declared serving as consultants/advisors or members of the speaker's bureau for or receiving honoraria, research funding, or travel and accommodation fees from various sources, including Amgen.

Source: Rossini D et al. Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer: The phase III TRIPLETE Study by GONO. J Clin Oncol. 2022 (Jun 6). Doi: 10.1200/JCO.22.00839

Key clinical point: The modified triplet (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan [mFOLFOXIRI]) + panitumumab vs. the doublet (fluorouracil, leucovorin, and oxaliplatin [FOLFOX]) + panitumumab does not show improved activity as initial therapy for RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC).

Major finding: Patients receiving mFOLFOXIRI + panitumumab vs. FOLFOX + panitumumab showed no significant difference in the objective response rate (73% vs. 76%; odds ratio 0.87; P = .526) and median progression-free survival (12.7 vs. 12.3 months; hazard ratio 0.88; P = .277).

Study details: Findings are from the phase 3 TRIPLETE study that included 435 adult patients with RAS and BRAF wt mCRC who were randomly assigned to receive mFOLFOXIRI + panitumumab (n = 218) or FOLFOX + panitumumab (n = 217).

Disclosures: The study was supported by the GONO Foundation and Amgen. Some authors declared serving as consultants/advisors or members of the speaker's bureau for or receiving honoraria, research funding, or travel and accommodation fees from various sources, including Amgen.

Source: Rossini D et al. Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer: The phase III TRIPLETE Study by GONO. J Clin Oncol. 2022 (Jun 6). Doi: 10.1200/JCO.22.00839

Key clinical point: Greater glycemic variability measured as the coefficient of variation for glucose (%CV) level was associated with a higher risk for all-cause mortality in patients with type 2 diabetes (T2D) and a well-controlled glucose status.

Major finding: Compared with patients with a %CV level of ≤20%, those with a %CV level of 20%-25% (adjusted HR [aHR] 1.16; 95% CI 0.78-1.73), 25%-30% (aHR 1.38; 95% CI 0.89-2.15), 30%-35% (aHR 1.33; 95% CI 0.77-2.29), and >35% (aHR 2.26; 95% CI 1.13-4.52) had a higher risk for all-cause mortality.

Study details: This study was a part of the INDIGO study including 1839 patients with T2D who reached continuous glucose monitoring glycemic targets and were classified into five groups by %CV level.

Disclosures: This study was supported by the National Key R&D Program of China, the National Natural Science Foundation of China, and others. The authors declared no conflicts of interest.

Source: Mo Y et al. Impact of short-term glycemic variability on risk of all-cause mortality in type 2 diabetes patients with well-controlled glucose profile by continuous glucose monitoring: A prospective cohort study. Diabetes Res Clin Pract. 2022;189:109940 (Jun 1). Doi: 10.1016/j.diabres.2022.109940

Key clinical point: Greater glycemic variability measured as the coefficient of variation for glucose (%CV) level was associated with a higher risk for all-cause mortality in patients with type 2 diabetes (T2D) and a well-controlled glucose status.

Major finding: Compared with patients with a %CV level of ≤20%, those with a %CV level of 20%-25% (adjusted HR [aHR] 1.16; 95% CI 0.78-1.73), 25%-30% (aHR 1.38; 95% CI 0.89-2.15), 30%-35% (aHR 1.33; 95% CI 0.77-2.29), and >35% (aHR 2.26; 95% CI 1.13-4.52) had a higher risk for all-cause mortality.

Study details: This study was a part of the INDIGO study including 1839 patients with T2D who reached continuous glucose monitoring glycemic targets and were classified into five groups by %CV level.

Disclosures: This study was supported by the National Key R&D Program of China, the National Natural Science Foundation of China, and others. The authors declared no conflicts of interest.

Source: Mo Y et al. Impact of short-term glycemic variability on risk of all-cause mortality in type 2 diabetes patients with well-controlled glucose profile by continuous glucose monitoring: A prospective cohort study. Diabetes Res Clin Pract. 2022;189:109940 (Jun 1). Doi: 10.1016/j.diabres.2022.109940

Key clinical point: Greater glycemic variability measured as the coefficient of variation for glucose (%CV) level was associated with a higher risk for all-cause mortality in patients with type 2 diabetes (T2D) and a well-controlled glucose status.

Major finding: Compared with patients with a %CV level of ≤20%, those with a %CV level of 20%-25% (adjusted HR [aHR] 1.16; 95% CI 0.78-1.73), 25%-30% (aHR 1.38; 95% CI 0.89-2.15), 30%-35% (aHR 1.33; 95% CI 0.77-2.29), and >35% (aHR 2.26; 95% CI 1.13-4.52) had a higher risk for all-cause mortality.

Study details: This study was a part of the INDIGO study including 1839 patients with T2D who reached continuous glucose monitoring glycemic targets and were classified into five groups by %CV level.

Disclosures: This study was supported by the National Key R&D Program of China, the National Natural Science Foundation of China, and others. The authors declared no conflicts of interest.

Source: Mo Y et al. Impact of short-term glycemic variability on risk of all-cause mortality in type 2 diabetes patients with well-controlled glucose profile by continuous glucose monitoring: A prospective cohort study. Diabetes Res Clin Pract. 2022;189:109940 (Jun 1). Doi: 10.1016/j.diabres.2022.109940